<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12785726</article-id><article-id pub-id-type="pmcid-ver">PMC12785726.1</article-id><article-id pub-id-type="pmcaid">12785726</article-id><article-id pub-id-type="pmcaiid">12785726</article-id><article-id pub-id-type="pmid">41516308</article-id><article-id pub-id-type="doi">10.3390/ijms27010421</article-id><article-id pub-id-type="publisher-id">ijms-27-00421</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mitigating Hydroxychloroquine-Induced Oxidative Liver Damage: The Roles of Adenosine Triphosphate, Liv-52, and Their Combination in Rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kandefer</surname><given-names initials="MY">Meryem Yalvac</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref ref-type="aff" rid="af1-ijms-27-00421">1</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3491-9798</contrib-id><name name-style="western"><surname>Sezgin</surname><given-names initials="ET">Esra Tuba</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref ref-type="aff" rid="af2-ijms-27-00421">2</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5795-3177</contrib-id><name name-style="western"><surname>Suleyman</surname><given-names initials="B">Bahadir</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref ref-type="aff" rid="af3-ijms-27-00421">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cimen</surname><given-names initials="FK">Ferda Keskin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref ref-type="aff" rid="af4-ijms-27-00421">4</xref><xref ref-type="corresp" rid="c1-ijms-27-00421">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2702-3160</contrib-id><name name-style="western"><surname>Memiş</surname><given-names initials="F">Fulya</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref ref-type="aff" rid="af1-ijms-27-00421">1</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3248-1502</contrib-id><name name-style="western"><surname>Gulaboglu</surname><given-names initials="M">Mine</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref ref-type="aff" rid="af5-ijms-27-00421">5</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9239-4099</contrib-id><name name-style="western"><surname>Suleyman</surname><given-names initials="H">Halis</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref ref-type="aff" rid="af3-ijms-27-00421">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Tomasello</surname><given-names initials="B">Barbara</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-27-00421"><label>1</label>Department of Internal Medicine, Mengucek Gazi Education and Research Hospital, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey; <email>meryemyalvac@hotmail.com</email> (M.Y.K.); <email>fozel57@gmail.com</email> (F.M.)</aff><aff id="af2-ijms-27-00421"><label>2</label>Anesthesia Program, Vocational School of Health Services, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey; <email>esra.demir@erzincan.edu.tr</email></aff><aff id="af3-ijms-27-00421"><label>3</label>Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey; <email>bahadirsuleyman@yandex.com</email> (B.S.); <email>halis.suleyman@gmail.com</email> (H.S.)</aff><aff id="af4-ijms-27-00421"><label>4</label>Department of Medical Pathology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey</aff><aff id="af5-ijms-27-00421"><label>5</label>Department of Biochemistry, Faculty of Pharmacy, Ataturk University, Erzurum 25240, Turkey; <email>minegulaboglu@atauni.edu.tr</email></aff><author-notes><corresp id="c1-ijms-27-00421"><label>*</label>Correspondence: <email>ferdakeskinn@hotmail.com</email>; Tel.: +90-505-8153095; Fax: +90-446-2261819</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>27</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">503380</issue-id><elocation-id>421</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-11 04:25:13.993"><day>11</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution (CC BY) license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ijms-27-00421.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><p>Hydroxychloroquine (HCQ), originally developed as an antimalarial agent, has been associated with hepatotoxic effects in experimental and clinical settings. Our study was designed to evaluate the effects of this agent on liver toxicity and to understand the protective roles of adenosine triphosphate (ATP), Liver-52 (Liv-52), and their combination. Male Wistar rats (250–280 g) were randomly assigned to five groups (n = 6): healthy control (C), HCQ only (H), ATP plus HCQ (AH), Liv-52 plus HCQ (LH), and ATP–Liv-52 plus HCQ (ALH). ATP (4 mg/kg) was administered intraperitoneally once daily, whereas Liv-52 (20 mg/kg) was administered orally via gavage. One hour later, all groups except C received HCQ (120 mg/kg, orally, twice daily). All treatments were continued for seven consecutive days. At the end of the experiment, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured, and liver tissues were analyzed for malondialdehyde (MDA), total glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) activities, along with histopathological evaluation. HCQ administration significantly increased oxidative stress, as evidenced by elevated MDA levels (<italic toggle="yes">p</italic> &lt; 0.01) and reduced antioxidant parameters, including GSH, SOD, and CAT (<italic toggle="yes">p</italic> &lt; 0.05), accompanied by prominent histopathological damage. Treatment with ATP or Liv-52 markedly ameliorated these alterations by decreasing MDA and restoring antioxidant markers. The combination treatment was observed to exhibit the most pronounced protective effect; it significantly reduced MDA levels, improved GSH, SOD, and CAT levels more effectively, and produced significant decreases in AST and ALT values (<italic toggle="yes">p</italic> &lt; 0.05). </p></abstract><kwd-group><kwd>ATP</kwd><kwd>HCQ</kwd><kwd>Liv-52</kwd><kwd>liver damage</kwd><kwd>oxidative stress</kwd><kwd>rats</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-ijms-27-00421" sec-type="intro"><title>1. Introduction</title><p>HCQ is a 4-aminoquinoline derivative drug that was initially used as an antimalarial agent [<xref ref-type="bibr" rid="B1-ijms-27-00421">1</xref>]. In subsequent years, with the elucidation of its anti-inflammatory properties, it began to be utilized in the treatment of various rheumatic diseases, most notably rheumatoid arthritis [<xref ref-type="bibr" rid="B2-ijms-27-00421">2</xref>,<xref ref-type="bibr" rid="B3-ijms-27-00421">3</xref>]. Authorized for use in the United States in 1994, the indications for HCQ have expanded over time, and it was utilized in the treatment of COVID-19 during the pandemic due to its antiviral potential [<xref ref-type="bibr" rid="B2-ijms-27-00421">2</xref>,<xref ref-type="bibr" rid="B4-ijms-27-00421">4</xref>]. While it generally exhibits a safe profile, various side effects associated with HCQ use have been reported in the literature [<xref ref-type="bibr" rid="B5-ijms-27-00421">5</xref>]. Particularly during the COVID-19 pandemic, serious adverse effects such as hepatotoxicity, cardiotoxicity, severe skin reactions, and suicidality have garnered attention [<xref ref-type="bibr" rid="B6-ijms-27-00421">6</xref>]. Indeed, a significant increase, up to ten times, in serum transaminase levels was observed following HCQ administration in a patient diagnosed with COVID-19, highlighting the hepatotoxic potential of this drug [<xref ref-type="bibr" rid="B7-ijms-27-00421">7</xref>]. Furthermore, acute severe liver damage related to HCQ has also been confirmed by liver biopsy [<xref ref-type="bibr" rid="B8-ijms-27-00421">8</xref>]. Current findings suggest that HCQ-related toxicity may occur through a multifactorial mechanism, including oxidative stress [<xref ref-type="bibr" rid="B9-ijms-27-00421">9</xref>]. Previous studies have shown that HCQ can affect various signaling pathways associated with oxidative stress, including PI3K/Akt, Nrf2, and NF-κB. These pathways play critical roles in regulating antioxidant defense and inflammatory responses. Dysregulation of these mechanisms may lead to excessive production of reactive oxygen species (ROS), increased lipid peroxidation, reduced antioxidant enzyme levels, and ultimately hepatocellular damage [<xref ref-type="bibr" rid="B10-ijms-27-00421">10</xref>]. Additionally, it has been shown that HCQ reduces intracellular ATP [<xref ref-type="bibr" rid="B11-ijms-27-00421">11</xref>].</p><p>ATP, a nucleotide comprising adenine, ribose sugar, and three phosphate groups, plays a central role in cellular energy metabolism [<xref ref-type="bibr" rid="B12-ijms-27-00421">12</xref>]. Intracellular ATP is involved in the synthesis of antioxidants that participate in the elimination of ROS, providing the necessary energy for these processes [<xref ref-type="bibr" rid="B13-ijms-27-00421">13</xref>,<xref ref-type="bibr" rid="B14-ijms-27-00421">14</xref>]. The literature indicates that ATP deficiency may trigger cellular necrosis [<xref ref-type="bibr" rid="B15-ijms-27-00421">15</xref>,<xref ref-type="bibr" rid="B16-ijms-27-00421">16</xref>]. This information suggests that antioxidant therapies could be beneficial in preventing HCQ-induced oxidative liver damage. Liv-52, a multi-herbal tablet formulation composed of extracts of <italic toggle="yes">Cichorium intybus</italic>, <italic toggle="yes">Cassia occidentalis</italic>, <italic toggle="yes">Capparis spinosa</italic>, <italic toggle="yes">Solanum nigrum</italic>, <italic toggle="yes">Terminalia arjuna</italic>, <italic toggle="yes">Achillea millefolium</italic> and <italic toggle="yes">Tamarix gallica</italic> is known for its effects in preventing cytotoxicity induced by oxidative stress. Liv-52 inhibits mitochondrial β-oxidation of fatty acids due to its capacity to reduce lipid peroxidation (LPO), thereby decreasing MDA levels and preventing GSH depletion [<xref ref-type="bibr" rid="B17-ijms-27-00421">17</xref>,<xref ref-type="bibr" rid="B18-ijms-27-00421">18</xref>]. All of the aforementioned findings suggest that both ATP and Liv-52 may have protective potential against the possible oxidative liver damage induced by HCQ. However, there have been no studies investigating the protective effects of ATP, Liv-52, or their combination against HCQ hepatotoxicity. In this regard, the aim of our study is to evaluate the toxic effects of HCQ on liver tissue in rats and to investigate the possible hepatoprotective effects of ATP, Liv-52, and the combination of these two agents.</p></sec><sec id="sec2-ijms-27-00421" sec-type="results"><title>2. Results</title><sec id="sec2dot1-ijms-27-00421"><title>2.1. Biochemical Findings</title><sec id="sec2dot1dot1-ijms-27-00421"><title>2.1.1. The Outcomes of the MDA and tGSH Assays in Liver Tissue</title><p>HCQ administration caused marked oxidative injury by increasing MDA levels in liver tissue by 57% (<xref ref-type="fig" rid="ijms-27-00421-f001">Figure 1</xref>A). The difference in MDA levels between the healthy and HCQ groups was statistically significant (<italic toggle="yes">p</italic> &lt; 0.001). This HCQ-induced increase was significantly suppressed by both ATP (<italic toggle="yes">p</italic> &lt; 0.001) and Liv-52 (<italic toggle="yes">p</italic> &lt; 0.001) treatments. In contrast, MDA levels in the ALH group were decreased by 37%. </p><p>HCQ was also found to reduce tGSH levels in liver tissue by 43% (<xref ref-type="fig" rid="ijms-27-00421-f001">Figure 1</xref>B). The difference in tGSH levels between the healthy and HCQ groups was statistically significant (<italic toggle="yes">p</italic> &lt; 0.001). Administration of ATP (<italic toggle="yes">p</italic> &lt; 0.001) and Liv-52 (<italic toggle="yes">p</italic> &lt; 0.001) significantly attenuated the HCQ-induced decrease in tGSH levels. Conversely, a 73% increase in tGSH levels was observed in the ALH group.</p></sec><sec id="sec2dot1dot2-ijms-27-00421"><title>2.1.2. The Outcomes of the SOD and CAT Assays in Liver Tissue</title><p>HCQ administration caused a pronounced antioxidant impairment by reducing SOD and CAT activities in liver tissue by 50% (<xref ref-type="fig" rid="ijms-27-00421-f002">Figure 2</xref>A,B). Accordingly, SOD (<italic toggle="yes">p</italic> &lt; 0.001) and CAT (<italic toggle="yes">p</italic> &lt; 0.001) activities in the HCQ-treated group were significantly lower than those observed in the healthy group. This HCQ-induced reduction in antioxidant enzyme activities was significantly attenuated by both ATP (SOD and CAT, respectively, <italic toggle="yes">p</italic> &lt; 0.001; <italic toggle="yes">p</italic> &lt; 0.001) and Liv-52 (SOD and CAT, respectively, <italic toggle="yes">p</italic> &lt; 0.001; <italic toggle="yes">p</italic> &lt; 0.001) administrations. In contrast, ALH treatment increased SOD and CAT activities by 100%.</p></sec><sec id="sec2dot1dot3-ijms-27-00421"><title>2.1.3. The Outcomes of the Blood Serum ALT and AST Assays</title><p>HCQ administration caused marked hepatocellular injury by increasing serum ALT activity by 260% (<xref ref-type="fig" rid="ijms-27-00421-f003">Figure 3</xref>A). Accordingly, ALT activity in the HCQ-treated group was significantly higher than that observed in the healthy group (<italic toggle="yes">p</italic> &lt; 0.001). This HCQ-induced elevation in ALT activity was significantly attenuated by ATP administration (<italic toggle="yes">p</italic> &lt; 0.001). Notably, Liv-52 was more effective than ATP in preventing the HCQ-associated increase in ALT activity, and a significant difference was observed between the ATP and Liv-52 groups (<italic toggle="yes">p</italic> = 0.002). In contrast, ALH treatment reduced ALT levels by 73%.</p><p>HCQ treatment also resulted in a severe increase in serum AST activity, with AST levels elevated by 700% compared to the healthy group (<xref ref-type="fig" rid="ijms-27-00421-f003">Figure 3</xref>B). Consistently, AST activity in the HCQ group was significantly higher than that in the healthy group (<italic toggle="yes">p</italic> &lt; 0.001). ATP significantly reduced the HCQ-induced increase in AST activity (<italic toggle="yes">p</italic> &lt; 0.001), whereas Liv-52 exerted a more pronounced protective effect (<italic toggle="yes">p</italic> &lt; 0.001). A significant difference in AST activity was detected between the ATP and Liv-52 groups (<italic toggle="yes">p</italic> &lt; 0.001). Furthermore, the combined administration of ATP and Liv-52 prevented approximately 90% of the HCQ-induced elevation in AST activity.</p></sec></sec><sec id="sec2dot2-ijms-27-00421"><title>2.2. Histopathological Findings</title><p><xref ref-type="table" rid="ijms-27-00421-t001">Table 1</xref> summarizes the histopathological grading results from rat liver samples and the statistical comparisons based on <italic toggle="yes">p</italic>-values. As observed in <xref ref-type="fig" rid="ijms-27-00421-f004">Figure 4</xref>A, the C group exhibited healthy normal portal areas and parenchyma in the liver tissue. The liver tissue of the group treated solely with HCQ displayed severe parenchymal destruction, hemorrhage, edema, and significant dilation of congested blood vessels, indicating severe damage (Grade-3; <xref ref-type="fig" rid="ijms-27-00421-f004">Figure 4</xref>B,C). Some improvement was noted in the liver tissue of the AH group. However, moderate damage (Grade-2), characterized by dilated congested blood vessels, hemorrhage, and lymphocyte infiltration in the parenchyma, was still observed (<xref ref-type="fig" rid="ijms-27-00421-f004">Figure 4</xref>D). The liver tissue of the LH group displayed similar morphology to that of the ATP group, exhibiting moderate damage (Grade-2) with dilated congested blood vessels, hemorrhage, and lymphocyte infiltration (<xref ref-type="fig" rid="ijms-27-00421-f004">Figure 4</xref>E). As shown in <xref ref-type="fig" rid="ijms-27-00421-f004">Figure 4</xref>F, the best level of recovery from HCQ-induced tissue damage was observed in the ALH group, where ATP and Liv-52 were administered in combination. In this group, the liver tissue appeared close to C group with only a slight dilation of congested blood vessels.</p></sec></sec><sec id="sec3-ijms-27-00421" sec-type="discussion"><title>3. Discussion</title><p>This study assessed the protective effects of ATP, Liv-52, and their combination against HCQ-induced oxidative liver injury. HCQ markedly elevated hepatic MDA levels and reduced tGSH, SOD, and CAT, while also increasing serum transaminase levels. Originally developed as an antimalarial drug, HCQ is now used to treat immune-mediated rheumatic disorders such as systemic lupus erythematosus and rheumatoid arthritis [<xref ref-type="bibr" rid="B5-ijms-27-00421">5</xref>,<xref ref-type="bibr" rid="B19-ijms-27-00421">19</xref>]. Despite all of these therapeutic effects, HCQ has been associated with side effects such as cardiomyopathy, neuromyopathy, and hematological abnormalities [<xref ref-type="bibr" rid="B20-ijms-27-00421">20</xref>,<xref ref-type="bibr" rid="B21-ijms-27-00421">21</xref>]. In comparison to these adverse reactions, hepatotoxicity associated with HCQ has been reported less frequently, and its pathophysiology is not fully understood. The literature contains mostly case reports regarding this issue [<xref ref-type="bibr" rid="B7-ijms-27-00421">7</xref>,<xref ref-type="bibr" rid="B22-ijms-27-00421">22</xref>,<xref ref-type="bibr" rid="B23-ijms-27-00421">23</xref>]. Additionally, a limited number of reports have described fulminant liver failure [<xref ref-type="bibr" rid="B24-ijms-27-00421">24</xref>]. Studies have reported that oxidative stress is one of the important factors in the pathogenesis of HCQ-related toxicity [<xref ref-type="bibr" rid="B25-ijms-27-00421">25</xref>,<xref ref-type="bibr" rid="B26-ijms-27-00421">26</xref>,<xref ref-type="bibr" rid="B27-ijms-27-00421">27</xref>]. As known, oxidative stress is characterized by an increase in ROS production and a decrease in antioxidant defense mechanisms [<xref ref-type="bibr" rid="B28-ijms-27-00421">28</xref>]. Various studies have shown that HCQ administration leads to excessive ROS production in tissues, resulting in a significant increase in MDA levels, a byproduct of LPO [<xref ref-type="bibr" rid="B25-ijms-27-00421">25</xref>,<xref ref-type="bibr" rid="B26-ijms-27-00421">26</xref>]. Topak et al. reported that oral administration of HCQ in rats triggered oxidative stress by increasing MDA levels and adversely affected the fracture healing process [<xref ref-type="bibr" rid="B25-ijms-27-00421">25</xref>]. Similarly, Abou-khzam, F. and B. reported that oral administration of HCQ significantly elevated MDA levels in liver tissue of rats [<xref ref-type="bibr" rid="B29-ijms-27-00421">29</xref>]. However, there are also findings in the literature suggesting that HCQ has inhibitory effects on oxidative stress, supports antioxidant defense systems, and facilitates the repair of tissue damage [<xref ref-type="bibr" rid="B30-ijms-27-00421">30</xref>,<xref ref-type="bibr" rid="B31-ijms-27-00421">31</xref>]. The biochemical data from our study demonstrated that MDA levels were significantly increased in the liver tissues of animals treated with HCQ. These results align with some previous studies emphasizing the oxidizing effects of HCQ [<xref ref-type="bibr" rid="B25-ijms-27-00421">25</xref>,<xref ref-type="bibr" rid="B26-ijms-27-00421">26</xref>,<xref ref-type="bibr" rid="B29-ijms-27-00421">29</xref>], but they contradict other experimental studies that reported HCQ’s ability to suppress oxidative stress [<xref ref-type="bibr" rid="B30-ijms-27-00421">30</xref>,<xref ref-type="bibr" rid="B31-ijms-27-00421">31</xref>]. It is believed that the discrepancies in these findings may stem from methodological variables such as dosage, duration of administration, animal models, or the type of tissue evaluated. In the current literature, various studies have demonstrated that the use of antioxidant molecules has yielded positive results in mitigating oxidative stress induced by HCQ in tissues [<xref ref-type="bibr" rid="B29-ijms-27-00421">29</xref>,<xref ref-type="bibr" rid="B32-ijms-27-00421">32</xref>]. The findings of our study also support this observation. In animals treated with HCQ, a significant increase in oxidant capacity was observed; conversely, essential antioxidant defense mechanisms such as tGSH, SOD, and CAT were found to be significantly reduced. GSH is one of the most important antioxidant molecules in the intracellular environment, composed of glutamate, cysteine, and glycine [<xref ref-type="bibr" rid="B33-ijms-27-00421">33</xref>]. Particularly in drug-induced liver injury, insufficient hepatic GSH levels can lead to the formation of protein adducts in the mitochondria by toxic drug metabolites, resulting in mitochondrial dysfunction and cell death [<xref ref-type="bibr" rid="B34-ijms-27-00421">34</xref>]. Indeed, the literature indicates that HCQ depletes GSH stores in CD4+ T cells, increases mitochondrial superoxide production, and inhibits cell proliferation [<xref ref-type="bibr" rid="B35-ijms-27-00421">35</xref>]. In light of this information, the decrease in tGSH levels observed in our study due to HCQ supports the potential for hepatocellular damage. Additionally, it was noted that in parallel with the decrease in tGSH, the activities of SOD and CAT enzymes were also reduced in the HCQ-treated group. These enzymes form a primary line of defense against oxidative stress; their activities are evaluated as diagnostic and prognostic biomarkers in various diseases [<xref ref-type="bibr" rid="B36-ijms-27-00421">36</xref>]. Topak et al. reported that oral administration of HCQ in rats decreased SOD and CAT activity, negatively affecting fracture healing [<xref ref-type="bibr" rid="B25-ijms-27-00421">25</xref>]. These findings are consistent with the data from our study. On the other hand, some literature sources have also reported results indicating that HCQ is associated with higher GSH levels and increased SOD/CAT activity, thereby mitigating oxidative damage [<xref ref-type="bibr" rid="B31-ijms-27-00421">31</xref>,<xref ref-type="bibr" rid="B37-ijms-27-00421">37</xref>]. To evaluate HCQ-induced hepatocellular damage, blood serum levels of ALT and AST were measured from samples collected from the tail veins of the animals. Increases in these enzymes in serum are considered biochemical markers of hepatocyte damage and necrosis [<xref ref-type="bibr" rid="B38-ijms-27-00421">38</xref>]. In the literature, toxic effects on the liver in patients undergoing HCQ treatment have been documented with elevated serum AST and ALT levels, supported by various case reports [<xref ref-type="bibr" rid="B7-ijms-27-00421">7</xref>,<xref ref-type="bibr" rid="B21-ijms-27-00421">21</xref>,<xref ref-type="bibr" rid="B39-ijms-27-00421">39</xref>]. Additionally, Sayed et al. reported significant increases in serum ALT and AST levels along with the development of hepatocellular degeneration in a study they conducted on a fish species exposed to HCQ [<xref ref-type="bibr" rid="B10-ijms-27-00421">10</xref>]. The findings from our study are consistent with these data, showing that in the HCQ-treated group, serum ALT and AST levels were significantly higher compared to the healthy control group. A commonly used biomarker for assessing liver function, the AST/ALT ratio (De Ritis ratio), also holds clinical importance in differentiating hepatobiliary disorders [<xref ref-type="bibr" rid="B40-ijms-27-00421">40</xref>]. In our study, this ratio was calculated to be approximately 3.0 in the HCQ group, indicating AST dominance and serving as a finding supporting HCQ-induced hepatotoxicity. It is known that HCQ increases cellular ATP consumption and accelerates proton flow across the lysosomal membrane [<xref ref-type="bibr" rid="B15-ijms-27-00421">15</xref>]. ATP, ADP, and adenosine play crucial roles in the biotransformation and metabolism of xenobiotics in hepatocytes. They also function as extracellular signaling molecules involved in regulating various physiological and pathophysiological processes [<xref ref-type="bibr" rid="B41-ijms-27-00421">41</xref>]. A disruption of the proton gradient that directs ATP production in the mitochondria can trigger necrotic or apoptotic cell death in the liver [<xref ref-type="bibr" rid="B42-ijms-27-00421">42</xref>]. However, some literature sources indicate that ATP is an essential energy source for the synthesis of ROS-scavenging antioxidants; externally supplied ATP supplementation has been shown to protect organs against oxidative damage and improve their functions [<xref ref-type="bibr" rid="B43-ijms-27-00421">43</xref>,<xref ref-type="bibr" rid="B44-ijms-27-00421">44</xref>]. Furthermore, extracellular ATP mediates its effects primarily through purinergic receptors, which are pivotal in regulating oxidative stress responses and modulating inflammation within hepatic tissues [<xref ref-type="bibr" rid="B45-ijms-27-00421">45</xref>]. The findings of our study align with this literature. In animals treated with HCQ that received ATP supplementation, the increase in MDA levels in the liver tissue was significantly suppressed, and the decline in tGSH levels along with SOD and CAT enzyme activities was prevented. Furthermore, the increase in serum AST and ALT levels was also significantly hindered by ATP treatment. These results highlight the supportive effects of ATP on the antioxidant defense system and its role in reducing HCQ-induced hepatocyte damage. Liv-52 is a polyherbal Ayurvedic formulation that has been shown to have protective effects against hepatotoxicity induced by chemical agents, both in clinical and preclinical studies [<xref ref-type="bibr" rid="B17-ijms-27-00421">17</xref>,<xref ref-type="bibr" rid="B46-ijms-27-00421">46</xref>]. This preparation is indicated for the management of acute liver injury, viral hepatitis, early-stage cirrhosis, and radiotherapy-induced liver damage. Furthermore, it is commonly prescribed as an adjunct therapy during prolonged illness and the recovery process [<xref ref-type="bibr" rid="B47-ijms-27-00421">47</xref>]. The antioxidant properties of Liv-52 are widely recognized as one of the fundamental mechanisms underlying its hepatoprotective effects [<xref ref-type="bibr" rid="B48-ijms-27-00421">48</xref>]. Liv-52 inhibits mitochondrial β-oxidation of fatty acids due to its capacity to reduce LPO, thereby decreasing MDA levels and preventing GSH depletion [<xref ref-type="bibr" rid="B18-ijms-27-00421">18</xref>]. Various experimental studies conducted on animal models have reported that Liv-52 application reduces the oxidative stress environment in drug-induced liver injury and demonstrates significant hepatoprotective effects by lowering serum AST and ALT levels [<xref ref-type="bibr" rid="B45-ijms-27-00421">45</xref>,<xref ref-type="bibr" rid="B49-ijms-27-00421">49</xref>]. Indeed, Çimen et al. reported that Liv-52 significantly reduced both oxidative stress and histopathological damage in a liver ischemia/reperfusion model [<xref ref-type="bibr" rid="B48-ijms-27-00421">48</xref>]. Similarly, our findings indicate that Liv-52 exerts protective effects against HCQ-induced liver damage. Liv-52 reduced the increase in hepatic MDA levels and significantly preserved tGSH, SOD, and CAT, supporting its role in preventing oxidative stress-related injury. Both Liv-52 and ATP enhanced antioxidant defense, though Liv-52 was more effective in lowering serum AST and ALT levels. Notably, the combination therapy led to greater improvement, with biochemical parameters approaching those of the healthy controls, and the lack of statistical differences in AST and ALT levels suggests substantial attenuation of hepatocyte damage.</p><p>Histopathological examinations of liver tissue yielded results consistent with the biochemical findings. In the group treated with HCQ, severe parenchymal destruction, hemorrhage, edema, and significant vascular congestion were observed. These findings align with histopathological data describing HCQ-induced hepatocellular damage in the literature [<xref ref-type="bibr" rid="B21-ijms-27-00421">21</xref>]. While ATP and Liv-52 applications partially reduced histopathological damage, in the group where both agents were administered together, the liver tissue structure was found to be quite close to a healthy morphology, with minimal vascular congestion.</p><p>Our study has certain limitations. The dose–response relationship was not evaluated, and only an acute toxicity model was used. In addition, measuring ATP levels in the liver tissues of animals treated with Liv-52 could have contributed to a better understanding of its potential effects. Therefore, further studies investigating different doses, administration durations, and additional mechanisms are needed. The limited sample size in our study (n = 6) poses a restriction, particularly in the interpretation of small differences between groups. Therefore, the findings should be evaluated within this limitation. The absence of control groups treated with ATP or Liv-52 alone (in the absence of HCQ) is another limitation. This omission makes it difficult to determine whether these agents have independent effects on liver oxidation and histology. Since our initial aim was solely to investigate HCQ-induced liver injury and the potential protective effects of ATP and Liv-52, such control groups were not included in the study design. Another limitation is that the high-dose, short-duration HCQ regimen used in this study reflects an acute toxicity model and is restricted to animal experiments; therefore, the findings cannot be generalized to long-term or high-dose clinical treatment in humans and remain limited to a preclinical framework. Although we obtained important findings regarding the potential hepatoprotective effects of ATP, Liv-52, and their combination against HCQ-induced oxidative liver injury, the absence of evaluations of key oxidative stress regulators such as Nrf2 and GST, as well as inflammatory markers including IL-6, IL-10, TNF-α, and NF-κB, represents a significant limitation. Future advanced studies will clearly elucidate the mechanisms through which ATP and Liv-52 exert their hepatoprotective effects. The underlying mechanisms of the hepatoprotective effects of ATP and Liv-52 could be more clearly elucidated through advanced molecular analyses such as Western blot and qRT-PCR. Evaluating the effects of these agents on other organs affected by HCQ toxicity may also provide a broader perspective. Additionally, dose–response studies are needed to determine whether the protective effects observed in the acute model persist over the long term.</p></sec><sec id="sec4-ijms-27-00421"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-27-00421"><title>4.1. Animals</title><p>The experimental study was conducted using 30 male albino Wistar-type rats, with body weights ranging from 270 to 281 g and aged 9–10 weeks. The animals were procured from the Experimental Animals Application and Research Center of Erzincan Binali Yıldırım University. The animals were allocated into five groups at random, with each group exhibiting a similar mean body weight. Before the commencement of the experiment, the rats were kept in groups of six within standard laboratory wire cages (20 cm high, 35 cm wide, 55 cm long; floor area: 1925 cm<sup>2</sup>) to allow for acclimatization to the laboratory conditions. The housing environment was maintained on a 12 h light/12 h dark cycle, at a constant temperature of 22 °C, with relative humidity ranging from 30% to 70%. Animals were granted free access to tap water and a commercially available pelleted feed (laboratory animal chow; Bayramoglu Stock Company, Erzurum, Turkey) throughout the study. Experimental protocols adhered to the European Parliament and Council Directive 2010/63/EU (Approval ID: 2016-24-199) [<xref ref-type="bibr" rid="B50-ijms-27-00421">50</xref>] and were carried out in line with the ARRIVE reporting standards [<xref ref-type="bibr" rid="B51-ijms-27-00421">51</xref>]. All experimental procedures involving animals were performed in the laboratories of the Experimental Animal Application and Research center at Erzincan Binali Yıldırım University.</p></sec><sec id="sec4dot2-ijms-27-00421"><title>4.2. Chemicals</title><p>The hydroxychloroquine (Plaquenil<sup>®</sup> 200 mg tablet) used in this study was obtained from Sanofi (Istanbul, Turkey), thiopental sodium (Pental Sodyum<sup>®</sup> 0.5 g vial) from IE Ulagay (Istanbul, Turkey), ATP (10 mg/mL vial) was supplied by Zdorove Narodu (Kharkiv, Ukraine), and Liv-52 (Liv.52<sup>®</sup> tablet) was sourced from Himalaya Wellness Company (Bangalore, Karnataka, India).</p></sec><sec id="sec4dot3-ijms-27-00421"><title>4.3. Experimental Design and Grouping</title><sec id="sec4dot3dot1-ijms-27-00421"><title>4.3.1. Experimental Design</title><p>The sample size was determined to utilize the smallest number of animals permissible in accordance with the 4R requirements [<xref ref-type="bibr" rid="B52-ijms-27-00421">52</xref>]. Criteria including slumped posture, diminished mobility, and injuries inflicted by other animals were employed to remove subjects throughout the experiment and data points during analysis. No exclusions occurred throughout the experiment. The random number table was utilized to generate the randomization sequence. Cages and animals are assigned numbers to reduce potential confounding variables.</p></sec><sec id="sec4dot3dot2-ijms-27-00421"><title>4.3.2. Experimental Groups</title><p>The animals were randomly assigned to five experimental groups: healthy control (C), hydroxychloroquine only (H), ATP combined with HCQ (AH), Liv-52 combined with HCQ (LH), and a combination of ATP, Liv-52, and HCQ (ALH).</p></sec></sec><sec id="sec4dot4-ijms-27-00421"><title>4.4. Experiment Procedure</title><p>The ATHQG group (n = 6) received 4 mg/kg of ATP intraperitoneally (IP). The LVHQG group (n = 6) was given 20 mg/kg of Liv-52 orally via an oral gavage into the stomach [<xref ref-type="bibr" rid="B48-ijms-27-00421">48</xref>]. The ALH group (n = 6) received ATP + LIV-52 in the specified doses using the same method. Animals in the C (n = 6) and H (n = 6) groups administered an equivalent volume of distilled water as a solvent. One hour after receiving ATP, Liv-52 and distilled water, all of the rats except those in the C group were given 120 mg/kg of HCQ orally via an oral gavage into their stomachs, twice daily. The acute dose of 120 mg/kg used for HCQ administration was selected based on previous literature studies [<xref ref-type="bibr" rid="B21-ijms-27-00421">21</xref>,<xref ref-type="bibr" rid="B53-ijms-27-00421">53</xref>]. ATP and Liv-52 were used once daily. This procedure was repeated for a duration of one week. At the end of this period, all animals in the groups were sacrificed under high-dose thiopental sodium (50 mg/kg) anesthesia, and liver tissues were extracted. The levels of MDA, tGSH, SOD, and CAT were measured in the extracted liver tissues. ALT and AST activities were assessed in blood samples taken from the tail veins. The tissues were also examined histopathologically. The results obtained from all experimental groups were evaluated by comparison between groups.</p></sec><sec id="sec4dot5-ijms-27-00421"><title>4.5. Biochemical Analysis</title><sec id="sec4dot5dot1-ijms-27-00421"><title>4.5.1. Preparation of Samples</title><p>Approximately 1 g of liver tissue was excised from each rat and immediately rinsed with 0.9% sodium chloride solution to remove blood and debris. The samples were then homogenized under ice-cold conditions using a high-speed tissue homogenizer. Following homogenization, 2 mL of 1.15% potassium chloride (KCl) buffer (pH 7.4) was added to each sample. The homogenates were centrifuged at 10,000× <italic toggle="yes">g</italic> for 15 min at 4 °C, and the supernatants were collected for subsequent biochemical analyses. Levels of MDA and tGSH, as well as the enzymatic activities of SOD and CAT, were determined from the supernatant fractions. To ensure intergroup comparability, all biochemical values were normalized to total protein content and expressed as milligrams per gram of protein (mg/g protein).</p></sec><sec id="sec4dot5dot2-ijms-27-00421"><title>4.5.2. Determination of MDA, tGSH, SOD, CAT and Protein in Liver Tissue</title><p>The levels of MDA, GSH, and SOD in tissue samples were quantified using the protocols provided with their respective rat ELISA kits: MDA (Product No. 10009055), total GSH (Product No. 703002), and SOD (Product No. 706002), all from Cayman Chemical Co. (Ann Arbor, MI, USA). CAT activity was determined according to the method described by Goth [<xref ref-type="bibr" rid="B54-ijms-27-00421">54</xref>]. Protein concentrations were determined using the Bradford assay, which relies on the binding of Coomassie Brilliant Blue G-250 dye to proteins. The absorbance of the resulting complex was spectrophotometrically measured at 595 nm [<xref ref-type="bibr" rid="B55-ijms-27-00421">55</xref>].</p></sec><sec id="sec4dot5dot3-ijms-27-00421"><title>4.5.3. Determination of Blood Serum ALT and AST</title><p>Venous blood samples were collected into sterile tubes without anticoagulant. After complete clot formation, the serum was separated by centrifugation and stored at –80 °C for subsequent analyses. The activities of serum ALT and AST were determined spectrophotometrically as indicators of liver function using the Cobas 8000 automated analyzer (Roche Diagnostics GmbH, Mannheim, Germany) and commercially available assay kits (Roche Diagnostics GmbH, Mannheim, Germany), in accordance with the manufacturer’s instructions.</p></sec></sec><sec id="sec4dot6-ijms-27-00421"><title>4.6. Histopathological Analysis</title><p>Tissue samples from the subjects were fixed in 10% formaldehyde solution for a duration of 72 h. After fixation, tissue samples were embedded in cassettes and rinsed under running water for 24 h, followed by dehydration through ascending concentrations of ethanol (70%, 80%, 90% and 100%) to remove residual water. Liver tissues rendered transparent with xylol were embedded in paraffin blocks, and sections of 4–5 μm thickness were obtained using a microtome. The obtained sections were stained using Hematoxylin-eosin (H&amp;E) and subsequently examined and photographed using the Olympus DP2-SAL firmware program (Olympus<sup>®</sup> Inc., Tokyo, Japan). A blinded pathologist conducted the histopathological assessment for the study groups to ensure objective evaluation. Histopathological examination of liver tissue was performed for signs of parenchymal destruction, hemorrhage, interstitial edema, and vascular dilatation or congestion. All histopathological findings were assessed using a semi-quantitative scoring system: 0 = absent, 1 = mild, 2 = moderate and 3 = severe.</p></sec><sec id="sec4dot7-ijms-27-00421"><title>4.7. Statistical Analysis</title><p>All statistical analyses were performed using IBM SPSS Statistics for Windows, version 27.0 (IBM Corp., Armonk, NY, USA, 2020). <xref ref-type="fig" rid="ijms-27-00421-f001">Figure 1</xref>, <xref ref-type="fig" rid="ijms-27-00421-f002">Figure 2</xref>, <xref ref-type="fig" rid="ijms-27-00421-f003">Figure 3</xref> and <xref ref-type="fig" rid="ijms-27-00421-f004">Figure 4</xref> were generated using GraphPad Prism 8.0.1 (GraphPad Software, San Diego, CA, USA, 2018). All biochemical data are presented as mean ± standard deviation. The assumption of normality was assessed using the Shapiro–Wilk test. To evaluate mean differences between groups, one-way ANOVA or Welch’s ANOVA was used when the normality assumption was met. When normality was satisfied, the homogeneity of variances assumption was assessed using Levene’s test. Pairwise comparisons were performed using Tukey’s honestly significant difference (HSD) post hoc test following one-way ANOVA when homogeneity of variances was confirmed, or using the Games–Howell post hoc test following Welch’s ANOVA when the assumption was violated. Histopathological data are expressed as medians with corresponding ranges (minimum–maximum). To evaluate differences among groups for histopathological outcomes, the Kruskal–Wallis test was applied; when significant, Dunn’s test with Bonferroni correction was used for pairwise comparisons, and adjusted <italic toggle="yes">p</italic>-values are presented. The findings were considered statistically significant when <italic toggle="yes">p</italic>-values were below 0.05.</p></sec></sec><sec id="sec5-ijms-27-00421" sec-type="conclusions"><title>5. Conclusions</title><p>The effects of HCQ on liver tissue in rats were investigated using biochemical and histopathological methods. Our experimental results indicate that oxidative stress developed in the liver tissue of animals treated with HCQ. It was demonstrated that both ATP and Liv-52, administered separately and in combination, provided significant protective effects against HCQ-induced hepatotoxicity. The combination treatment was observed to exhibit the most pronounced protective effect; it significantly reduced MDA levels, improved GSH, SOD, and CAT levels more effectively, and produced significant decreases in AST and ALT values (<italic toggle="yes">p</italic> &lt; 0.05). The best level of recovery from HCQ-induced tissue damage was observed in the ALH group, where ATP and Liv-52 were administered in combination. In conclusion, the findings suggest that ATP and Liv-52 may exert a potential protective effect in reducing acute HCQ-induced liver injury in a preclinical context.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.Y.K.: Conceptualization, Formal Analysis, Funding Acquisition, Project Administration, Resources, Supervision, Validation, Visualization, Writing—Original Draft, Writing—Review &amp; Editing; E.T.S.: Data Curation, Formal Analysis, Investigation, Software, Resources, Visualization, Writing—Original Draft, Writing—Review &amp; Editing; B.S.: Investigation, Methodology, Resources, Supervision, Writing—Original Draft, Writing—Review &amp; Editing; F.K.C.: Data Curation, Formal Analysis, Investigation, Validation, Writing—Original Draft, Writing—Review &amp; Editing; F.M.: Conceptualization, Formal Analysis, Funding Acquisition, Project Administration; M.G.: Data Curation, Formal Analysis, Investigation, Validation, Writing—Original Draft, Writing—Review &amp; Editing; H.S.: Conceptualization, Formal Analysis, Methodology, Project Administration, Supervision, Validation, Writing—Original Draft, Writing—Review &amp; Editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All animal-related procedures received prior approval from the local Ethics Committee for animal experiments at Erzincan Binali Yıldırım University (Erzincan, Turkey; Session Date: 27 April 2025; Session No: 2025/04; Approval No: 22).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data from the research can be obtained from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" colspan="1" rowspan="1" valign="middle">HCQ</td><td align="left" colspan="1" rowspan="1" valign="middle">Hydroxychloroquine</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">MDA</td><td align="left" colspan="1" rowspan="1" valign="middle">Malondialdehyde</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">tGSH</td><td align="left" colspan="1" rowspan="1" valign="middle">Total Glutathione</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">SOD</td><td align="left" colspan="1" rowspan="1" valign="middle">Superoxid Dismutase</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">CAT</td><td align="left" colspan="1" rowspan="1" valign="middle">Catalase</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ATP</td><td align="left" colspan="1" rowspan="1" valign="middle">Adenosine Triphosphate</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ALT</td><td align="left" colspan="1" rowspan="1" valign="middle">Alanine Aminotransferase</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">AST</td><td align="left" colspan="1" rowspan="1" valign="middle">Aspartate Aminotransferase</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ROS</td><td align="left" colspan="1" rowspan="1" valign="middle">Reactive Oxygen Species</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">ELISA</td><td align="left" colspan="1" rowspan="1" valign="middle">Enzyme-linked Immunosorbent Assay</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="middle">LPO</td><td align="left" colspan="1" rowspan="1" valign="middle">Lipid Peroxidation</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-ijms-27-00421"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bansal</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Goyal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Cusick</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Lahan</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Dhaliwal</surname><given-names>H.S.</given-names></name>
<name name-style="western"><surname>Bhyan</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Bhattad</surname><given-names>P.B.</given-names></name>
<name name-style="western"><surname>Aslam</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Ranka</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Dalia</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019</article-title><source>Ann. Med.</source><year>2020</year><volume>53</volume><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1080/07853890.2020.1839959</pub-id><pub-id pub-id-type="pmcid">PMC7880079</pub-id><pub-id pub-id-type="pmid">33095083</pub-id></element-citation></ref><ref id="B2-ijms-27-00421"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>LiverTox</collab>
</person-group><article-title>Hydroxychloroquine</article-title><source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</source><publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2012</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548738/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ncbi.nlm.nih.gov/books/NBK548738/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-11-05">(accessed on 5 November 2025)</date-in-citation></element-citation></ref><ref id="B3-ijms-27-00421"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Stokkermans</surname><given-names>T.J.</given-names></name>
<name name-style="western"><surname>Falkowitz</surname><given-names>D.M.</given-names></name>
<name name-style="western"><surname>Trichonas</surname><given-names>G.</given-names></name>
</person-group><article-title>Chloroquine and Hydroxychloroquine Toxicity</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><pub-id pub-id-type="pmid">30725771</pub-id></element-citation></ref><ref id="B4-ijms-27-00421"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lei</surname><given-names>Z.-N.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Z.-X.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>D.-H.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ke</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zou</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Z.-S.</given-names></name>
</person-group><article-title>Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>216</volume><fpage>107672</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107672</pub-id><pub-id pub-id-type="pmid">32910933</pub-id><pub-id pub-id-type="pmcid">PMC7476892</pub-id></element-citation></ref><ref id="B5-ijms-27-00421"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Huo</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name>
</person-group><article-title>Hydroxychloroquine: A double-edged sword (Review)</article-title><source>Mol. Med. Rep.</source><year>2025</year><volume>31</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.3892/mmr.2025.13467</pub-id><pub-id pub-id-type="pmid">39981928</pub-id><pub-id pub-id-type="pmcid">PMC11868775</pub-id></element-citation></ref><ref id="B6-ijms-27-00421"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sainz-Gil</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kolly</surname><given-names>N.M.</given-names></name>
<name name-style="western"><surname>Velasco-González</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Rello</surname><given-names>Z.V.</given-names></name>
<name name-style="western"><surname>Fernandez-Araque</surname><given-names>A.M.</given-names></name>
<name name-style="western"><surname>Fadrique</surname><given-names>R.S.</given-names></name>
<name name-style="western"><surname>Arias</surname><given-names>L.H.M.</given-names></name>
</person-group><article-title>Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: Analysis of differences and potential interactions</article-title><source>Expert Opin. Drug Saf.</source><year>2022</year><volume>22</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1080/14740338.2022.2078303</pub-id><pub-id pub-id-type="pmid">35574687</pub-id></element-citation></ref><ref id="B7-ijms-27-00421"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Falcão</surname><given-names>M.B.</given-names></name>
<name name-style="western"><surname>Cavalcanti</surname><given-names>L.P.d.G.</given-names></name>
<name name-style="western"><surname>Filho</surname><given-names>N.M.F.</given-names></name>
<name name-style="western"><surname>de Brito</surname><given-names>C.A.A.</given-names></name>
</person-group><article-title>Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2020</year><volume>102</volume><fpage>1214</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.20-0276</pub-id><pub-id pub-id-type="pmid">32314698</pub-id><pub-id pub-id-type="pmcid">PMC7253107</pub-id></element-citation></ref><ref id="B8-ijms-27-00421"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gişi</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>İspiroğlu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kilinç</surname><given-names>E.</given-names></name>
</person-group><article-title>A Hydroxychloroquine-Related Acute Severe Liver Disease</article-title><source>Turk. Klin. J. Case Rep.</source><year>2022</year><volume>30</volume><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.5336/caserep.2021-87036</pub-id></element-citation></ref><ref id="B9-ijms-27-00421"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Della Porta</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bornstein</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Coye</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Montrief</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Long</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Parris</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians</article-title><source>Am. J. Emerg. Med.</source><year>2020</year><volume>38</volume><fpage>2209</fpage><lpage>2217</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2020.07.030</pub-id><pub-id pub-id-type="pmid">33071096</pub-id><pub-id pub-id-type="pmcid">PMC7369162</pub-id></element-citation></ref><ref id="B10-ijms-27-00421"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>El-Samad</surname><given-names>L.M.</given-names></name>
<name name-style="western"><surname>Maklad</surname><given-names>A.M.</given-names></name>
<name name-style="western"><surname>Elkady</surname><given-names>A.I.</given-names></name>
<name name-style="western"><surname>Hassan</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Unveiling the Mechanism of Sericin and Hydroxychloroquine in Suppressing Lung Oxidative Impairment and Early Carcinogenesis in Diethylnitrosamine-Induced Mice by Modulating PI3K/Akt/Nrf2/NF-κB Signaling Pathway</article-title><source>Biomed. Pharmacother.</source><year>2025</year><volume>182</volume><fpage>117730</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2024.117730</pub-id><pub-id pub-id-type="pmid">39671723</pub-id></element-citation></ref><ref id="B11-ijms-27-00421"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Sheaff</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Hussaini</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Chloroquine-Based Mitochondrial ATP Inhibitors</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>1161</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28031161</pub-id><pub-id pub-id-type="pmid">36770828</pub-id><pub-id pub-id-type="pmcid">PMC9920964</pub-id></element-citation></ref><ref id="B12-ijms-27-00421"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Dunn</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Grider</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Physiology, Adenosine Triphosphate</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><pub-id pub-id-type="pmid">31985968</pub-id></element-citation></ref><ref id="B13-ijms-27-00421"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Saquet</surname><given-names>A.A.</given-names></name>
<name name-style="western"><surname>Streif</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bangerth</surname><given-names>F.</given-names></name>
</person-group><article-title>Changes in ATP, ADP and pyridine nucleotide levels related to the incidence of physiological disorders in ‘Conference’ pears and ‘Jonagold’ apples during controlled atmosphere storage</article-title><source>J. Hortic. Sci. Biotechnol.</source><year>2000</year><volume>75</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1080/14620316.2000.11511231</pub-id></element-citation></ref><ref id="B14-ijms-27-00421"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yi</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Qu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Xue</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Prasad</surname><given-names>N.K.</given-names></name>
</person-group><article-title>ATP-regulation of antioxidant properties and phenolics in litchi fruit during browning and pathogen infection process</article-title><source>Food Chem.</source><year>2010</year><volume>118</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2009.04.074</pub-id></element-citation></ref><ref id="B15-ijms-27-00421"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Klouda</surname><given-names>C.B.</given-names></name>
<name name-style="western"><surname>Stone</surname><given-names>W.L.</given-names></name>
</person-group><article-title>Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><elocation-id>894</elocation-id><pub-id pub-id-type="doi">10.3390/antiox9090894</pub-id><pub-id pub-id-type="pmid">32967165</pub-id><pub-id pub-id-type="pmcid">PMC7555760</pub-id></element-citation></ref><ref id="B16-ijms-27-00421"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tsujimoto</surname><given-names>Y.</given-names></name>
</person-group><article-title>Apoptosis and necrosis: Intracellular ATP level as a determinant for cell death modes</article-title><source>Cell Death Differ.</source><year>1997</year><volume>4</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400262</pub-id><pub-id pub-id-type="pmid">16465263</pub-id></element-citation></ref><ref id="B17-ijms-27-00421"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shivnitwar</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Gilada</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Rajkondawar</surname><given-names>A.V.</given-names></name>
<name name-style="western"><surname>Ojha</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Katiyar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Arya</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Babu</surname><given-names>U.V.</given-names></name>
<name name-style="western"><surname>Kumawat</surname><given-names>R.</given-names></name>
</person-group><article-title>Safety and Effectiveness of Liv.52 DS in Patients With Varied Hepatic Disorders: An Open-Label, Multi-centre, Phase IV Study</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e60898</fpage><pub-id pub-id-type="doi">10.7759/cureus.60898</pub-id><pub-id pub-id-type="pmid">38784689</pub-id><pub-id pub-id-type="pmcid">PMC11112526</pub-id></element-citation></ref><ref id="B18-ijms-27-00421"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vidyashankar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>L.S.</given-names></name>
<name name-style="western"><surname>Barooah</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Varma</surname><given-names>R.S.</given-names></name>
<name name-style="western"><surname>Nandakumar</surname><given-names>K.S.</given-names></name>
<name name-style="western"><surname>Patki</surname></name>
<name name-style="western"><surname>Liv</surname><given-names>P.S.</given-names></name>
</person-group><article-title>52 up-regulates cellular antioxidants and increase glucose uptake to circumvent oleic acid induced hepatic steatosis in HepG2 cells</article-title><source>Phytomedicine</source><year>2012</year><volume>19</volume><fpage>1156</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.08.005</pub-id><pub-id pub-id-type="pmid">22940028</pub-id></element-citation></ref><ref id="B19-ijms-27-00421"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rainsford</surname><given-names>K.D.</given-names></name>
<name name-style="western"><surname>Parke</surname><given-names>A.L.</given-names></name>
<name name-style="western"><surname>Clifford-Rashotte</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kean</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases</article-title><source>Inflammopharmacology</source><year>2015</year><volume>23</volume><fpage>231</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1007/s10787-015-0239-y</pub-id><pub-id pub-id-type="pmid">26246395</pub-id></element-citation></ref><ref id="B20-ijms-27-00421"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Muller</surname><given-names>R.</given-names></name>
</person-group><article-title>Systemic toxicity of chloroquine and hydroxychloroquine: Prevalence, mechanisms, risk factors, prognostic and screening possibilities</article-title><source>Rheumatol. Int.</source><year>2021</year><volume>41</volume><fpage>1189</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1007/s00296-021-04868-6</pub-id><pub-id pub-id-type="pmid">33893862</pub-id><pub-id pub-id-type="pmcid">PMC8064887</pub-id></element-citation></ref><ref id="B21-ijms-27-00421"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Alruwaili</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Jarrar</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Jarrar</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Alruwaili</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Goh</surname><given-names>K.W.</given-names></name>
<name name-style="western"><surname>Moshawih</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ardianto</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Ming</surname><given-names>L.C.</given-names></name>
</person-group><article-title>Hydroxychloroquine Toxicity in the Vital Organs of the Body: In Vivo Study</article-title><source>Front. Biosci.</source><year>2023</year><volume>28</volume><elocation-id>137</elocation-id><pub-id pub-id-type="doi">10.31083/j.fbl2807137</pub-id><pub-id pub-id-type="pmid">37525906</pub-id></element-citation></ref><ref id="B22-ijms-27-00421"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Galil</surname><given-names>S.M.A.</given-names></name>
</person-group><article-title>Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: A case report</article-title><source>Lupus</source><year>2014</year><volume>24</volume><fpage>638</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1177/0961203314561667</pub-id><pub-id pub-id-type="pmid">25424894</pub-id></element-citation></ref><ref id="B23-ijms-27-00421"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gisi</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Ispiroglu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kilinc</surname><given-names>E.</given-names></name>
</person-group><article-title>A hydroxychloroquine-related acute liver failure case and review of the literature</article-title><source>J. Clin. Toxicol.</source><year>2021</year><volume>11</volume><fpage>1000004</fpage><pub-id pub-id-type="doi">10.35248/2161-0495.21.S16.E004</pub-id></element-citation></ref><ref id="B24-ijms-27-00421"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dima</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Jurcut</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Chasset</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Felten</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Arnaud</surname><given-names>L.</given-names></name>
</person-group><article-title>Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge</article-title><source>Ther. Adv. Musculoskelet. Dis.</source><year>2022</year><volume>14</volume><fpage>1759720X211073001</fpage><pub-id pub-id-type="doi">10.1177/1759720X211073001</pub-id><pub-id pub-id-type="pmcid">PMC8848057</pub-id><pub-id pub-id-type="pmid">35186126</pub-id></element-citation></ref><ref id="B25-ijms-27-00421"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Topak</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Gürbüz</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Doğar</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Bakır</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Gürbüz</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kılınç</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Bilal</surname><given-names>Ö.</given-names></name>
<name name-style="western"><surname>Eken</surname><given-names>A.</given-names></name>
</person-group><article-title>Hydroxychloroquine induces oxidative stress and impairs fracture healing in rats</article-title><source>Jt. Dis. Relat. Surg.</source><year>2023</year><volume>34</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.52312/jdrs.2023.976</pub-id><pub-id pub-id-type="pmid">37462638</pub-id><pub-id pub-id-type="pmcid">PMC10367152</pub-id></element-citation></ref><ref id="B26-ijms-27-00421"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Önaloğlu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Beytemür</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Saraç</surname><given-names>E.Y.</given-names></name>
<name name-style="western"><surname>Biçer</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Güleryüz</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Güleç</surname><given-names>M.A.</given-names></name>
</person-group><article-title>The effects of hydroxychloroquine-induced oxidative stress on fracture healing in an experimental rat model</article-title><source>Jt. Dis. Relat. Surg.</source><year>2023</year><volume>35</volume><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.52312/jdrs.2023.1226</pub-id><pub-id pub-id-type="pmid">38108176</pub-id><pub-id pub-id-type="pmcid">PMC10746893</pub-id></element-citation></ref><ref id="B27-ijms-27-00421"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Besaratinia</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Caliri</surname><given-names>A.W.</given-names></name>
<name name-style="western"><surname>Tommasi</surname><given-names>S.</given-names></name>
</person-group><article-title>Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells</article-title><source>DNA Repair</source><year>2021</year><volume>106</volume><fpage>103180</fpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2021.103180</pub-id><pub-id pub-id-type="pmid">34298488</pub-id><pub-id pub-id-type="pmcid">PMC8435022</pub-id></element-citation></ref><ref id="B28-ijms-27-00421"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Krishnamurthy</surname><given-names>H.K.</given-names></name>
<name name-style="western"><surname>Pereira</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Rajavelu</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Jayaraman</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Krishna</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Bei</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Rajasekaran</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Oxidative stress: Fundamentals and advances in quantification techniques</article-title><source>Front. Chem.</source><year>2024</year><volume>12</volume><elocation-id>1470458</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2024.1470458</pub-id><pub-id pub-id-type="pmid">39435263</pub-id><pub-id pub-id-type="pmcid">PMC11491411</pub-id></element-citation></ref><ref id="B29-ijms-27-00421"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Abou-Khzam</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Abou-Khzam</surname><given-names>B.</given-names></name>
</person-group><article-title>Physiological and Histological Studies on Moringa Effects Against Liver Toxicity Induced by Hydroxychloroquine in Rats</article-title><source>Libyan J. Ecol. Environ. Sci. Technol. (LJEEST)</source><year>2022</year><volume>4</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.63359/6g40dg27</pub-id></element-citation></ref><ref id="B30-ijms-27-00421"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Athari</surname><given-names>S.Z.</given-names></name>
<name name-style="western"><surname>Farajdokht</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Sadigh-Eteghad</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mohajeri</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Nourazar</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Mohaddes</surname><given-names>G.</given-names></name>
</person-group><article-title>Hydroxychloroquine attenuated motor impairment and oxidative stress in a rat 6-hydroxydopamine model of Parkinson’s disease</article-title><source>Int. J. Neurosci.</source><year>2022</year><volume>133</volume><fpage>1252</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1080/00207454.2022.2074848</pub-id><pub-id pub-id-type="pmid">35522252</pub-id></element-citation></ref><ref id="B31-ijms-27-00421"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ahmed</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Althanoon</surname><given-names>Z.A.</given-names></name>
</person-group><article-title>Effects of Hydroxychloroquine on markers of oxidative stress and antioxidant reserve in rheumatoid arthritis patients</article-title><source>J. Adv. Pharm. Educ. Res.</source><year>2022</year><volume>12</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.51847/7wv6zqfhb5</pub-id></element-citation></ref><ref id="B32-ijms-27-00421"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Amer</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mohamed</surname><given-names>N.</given-names></name>
</person-group><article-title>Potential Use of Quercetin as Protective Agent against Hydroxychloroquine Induced Cardiotoxicity</article-title><source>J. Biomed. Res. Environ. Sci.</source><year>2021</year><volume>2</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.37871/jbres1208</pub-id></element-citation></ref><ref id="B33-ijms-27-00421"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kauffmann</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>da Penha</surname><given-names>L.K.R.L.</given-names></name>
<name name-style="western"><surname>Braga</surname><given-names>D.V.</given-names></name>
<name name-style="western"><surname>Ataíde</surname><given-names>B.J.A.</given-names></name>
<name name-style="western"><surname>Mendes</surname><given-names>N.S.F.</given-names></name>
<name name-style="western"><surname>de Sousa</surname><given-names>L.P.</given-names></name>
<name name-style="western"><surname>da Souza</surname><given-names>G.S.</given-names></name>
<name name-style="western"><surname>Passos</surname><given-names>A.C.F.</given-names></name>
<name name-style="western"><surname>Batista</surname><given-names>E.J.O.</given-names></name>
<name name-style="western"><surname>Herculano</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group><article-title>Differential Effect of Antioxidants Glutathione and Vitamin C on the Hepatic Injuries Induced by Plasmodium berghei ANKA Infection</article-title><source>BioMed Res. Int.</source><year>2021</year><volume>2021</volume><fpage>9694508</fpage><pub-id pub-id-type="doi">10.1155/2021/9694508</pub-id><pub-id pub-id-type="pmid">34527745</pub-id><pub-id pub-id-type="pmcid">PMC8437662</pub-id></element-citation></ref><ref id="B34-ijms-27-00421"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Villanueva-Paz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Morán</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>López-Alcántara</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Freixo</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R.J.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Cubero</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><elocation-id>390</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10030390</pub-id><pub-id pub-id-type="pmid">33807700</pub-id><pub-id pub-id-type="pmcid">PMC8000729</pub-id></element-citation></ref><ref id="B35-ijms-27-00421"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kim</surname><given-names>M.L.</given-names></name>
<name name-style="western"><surname>Hardy</surname><given-names>M.Y.</given-names></name>
<name name-style="western"><surname>Edgington-Mitchell</surname><given-names>L.E.</given-names></name>
<name name-style="western"><surname>Ramarathinam</surname><given-names>S.H.</given-names></name>
<name name-style="western"><surname>Chung</surname><given-names>S.Z.</given-names></name>
<name name-style="western"><surname>Russell</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Currie</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Sleebs</surname><given-names>B.E.</given-names></name>
<name name-style="western"><surname>Purcell</surname><given-names>A.W.</given-names></name>
<name name-style="western"><surname>Tye-Din</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>103509</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.103509</pub-id><pub-id pub-id-type="pmid">34934928</pub-id><pub-id pub-id-type="pmcid">PMC8661543</pub-id></element-citation></ref><ref id="B36-ijms-27-00421"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hamam</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Demir</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Aydin</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Demir</surname><given-names>C.</given-names></name>
</person-group><article-title>Determination of some Antioxidant Activities (Superoxide Dismutase, Catalase, Reduced Glutathione) and Oxidative Stress Level (Malondialdehyde Acid) in Cirrhotic Liver Patients</article-title><source>Middle Black Sea J. Heal. Sci.</source><year>2022</year><volume>8</volume><fpage>506</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.19127/mbsjohs.1108726</pub-id></element-citation></ref><ref id="B37-ijms-27-00421"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hasan</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Ammar</surname><given-names>O.A.</given-names></name>
<name name-style="western"><surname>Amer</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Othman</surname><given-names>A.I.</given-names></name>
<name name-style="western"><surname>Zigheber</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>El-Missiry</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Hydroxychloroquine improves high-fat-diet-induced obesity and organ dysfunction via modulation of lipid level, oxidative stress, and inflammation</article-title><source>Egypt. J. Basic Appl. Sci.</source><year>2023</year><volume>10</volume><fpage>368</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1080/2314808X.2023.2211832</pub-id></element-citation></ref><ref id="B38-ijms-27-00421"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kalas</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Chavez</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Leon</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Taweesedt</surname><given-names>P.T.</given-names></name>
<name name-style="western"><surname>Surani</surname><given-names>S.</given-names></name>
</person-group><article-title>Abnormal liver enzymes: A review for clinicians</article-title><source>World J. Hepatol.</source><year>2021</year><volume>13</volume><fpage>1688</fpage><lpage>1698</lpage><pub-id pub-id-type="doi">10.4254/wjh.v13.i11.1688</pub-id><pub-id pub-id-type="pmid">34904038</pub-id><pub-id pub-id-type="pmcid">PMC8637680</pub-id></element-citation></ref><ref id="B39-ijms-27-00421"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Pham</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Kaur</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yip</surname><given-names>K.</given-names></name>
</person-group><article-title>Hydroxychloroquine-Induced Hepatotoxicity in Systemic Lupus Erythematous: A Case Report and Literature Review</article-title><source>Cureus</source><year>2025</year><volume>17</volume><fpage>e81664</fpage><pub-id pub-id-type="doi">10.7759/cureus.81664</pub-id><pub-id pub-id-type="pmid">40322400</pub-id><pub-id pub-id-type="pmcid">PMC12049183</pub-id></element-citation></ref><ref id="B40-ijms-27-00421"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shaikh</surname><given-names>S.M.</given-names></name>
<name name-style="western"><surname>Varma</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Acharya</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Patil</surname><given-names>R.</given-names></name>
</person-group><article-title>Navigating Disease Management: A Comprehensive Review of the De Ritis Ratio in Clinical Medicine</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e64447</fpage><pub-id pub-id-type="doi">10.7759/cureus.64447</pub-id><pub-id pub-id-type="pmid">39139333</pub-id><pub-id pub-id-type="pmcid">PMC11319523</pub-id></element-citation></ref><ref id="B41-ijms-27-00421"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jacobson</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Purinergic Signaling in Liver Pathophysiology</article-title><source>Front. Endocrinol.</source><year>2021</year><volume>12</volume><elocation-id>718429</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2021.718429</pub-id><pub-id pub-id-type="pmid">34456873</pub-id><pub-id pub-id-type="pmcid">PMC8385492</pub-id></element-citation></ref><ref id="B42-ijms-27-00421"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nishikawa</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Bellance</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Damm</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bing</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Handa</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Yovchev</surname><given-names>M.I.</given-names></name>
<name name-style="western"><surname>Sehgal</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Moss</surname><given-names>T.J.</given-names></name>
<name name-style="western"><surname>Oertel</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease</article-title><source>J. Hepatol.</source><year>2014</year><volume>60</volume><fpage>1203</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.02.014</pub-id><pub-id pub-id-type="pmid">24583248</pub-id><pub-id pub-id-type="pmcid">PMC4028384</pub-id></element-citation></ref><ref id="B43-ijms-27-00421"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ozer</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ince</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Altuner</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Cicek</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Gulaboglu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mokhtare</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Gursul</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>H.</given-names></name>
</person-group><article-title>Protective Effect of Adenosine Triphosphate against 5-Fluorouracil-Induced Oxidative Ovarian Damage in vivo</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2023</year><volume>24</volume><fpage>1007</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.31557/APJCP.2023.24.3.1007</pub-id><pub-id pub-id-type="pmid">36974556</pub-id><pub-id pub-id-type="pmcid">PMC10334103</pub-id></element-citation></ref><ref id="B44-ijms-27-00421"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ozbay</surname><given-names>A.D.</given-names></name>
<name name-style="western"><surname>Somuncu</surname><given-names>A.M.</given-names></name>
<name name-style="western"><surname>Cicek</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Yavuzer</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Bulut</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Huseynova</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Tastan</surname><given-names>T.B.</given-names></name>
<name name-style="western"><surname>Gulaboglu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>H.</given-names></name>
</person-group><article-title>Effects of adenosine triphosphate and coenzyme Q10 on potential hydroxychloroquine-induced retinal damage in rats</article-title><source>Exp. Eye Res.</source><year>2025</year><volume>255</volume><fpage>110387</fpage><pub-id pub-id-type="doi">10.1016/j.exer.2025.110387</pub-id><pub-id pub-id-type="pmid">40216064</pub-id></element-citation></ref><ref id="B45-ijms-27-00421"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Patrakeeva</surname><given-names>V.P.</given-names></name>
</person-group><article-title>The Role of Extracellular ATP in the Regulation of Functional Cell Activity</article-title><source>Cell Tissue Biol.</source><year>2025</year><volume>19</volume><fpage>206</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1134/S1990519X25030022</pub-id></element-citation></ref><ref id="B46-ijms-27-00421"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yildirim</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Lale</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Yazıcı</surname><given-names>G.N.</given-names></name>
<name name-style="western"><surname>Sunar</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Aktas</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ozcicek</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Ozcicek</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>H.</given-names></name>
</person-group><article-title>Ameliorative effects of Liv-52 on doxorubicin-induced oxidative damage in rat liver</article-title><source>Biotech. Histochem.</source><year>2022</year><volume>97</volume><fpage>616</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1080/10520295.2022.2065533</pub-id><pub-id pub-id-type="pmid">35527648</pub-id></element-citation></ref><ref id="B47-ijms-27-00421"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kantharia</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Jain</surname><given-names>M.K.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Jain</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Desai</surname><given-names>A.</given-names></name>
</person-group><article-title>Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review</article-title><source>Gastroenterol. Insights</source><year>2023</year><volume>14</volume><fpage>293</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.3390/gastroent14030021</pub-id></element-citation></ref><ref id="B48-ijms-27-00421"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cimen</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Eken</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Cimen</surname><given-names>F.K.</given-names></name>
<name name-style="western"><surname>Cekic</surname><given-names>A.B.</given-names></name>
<name name-style="western"><surname>Kurt</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Bilgin</surname><given-names>A.O.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Mammadov</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Pehlivanoglu</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The effect of Liv-52 on liver ischemia reperfusion damage in rats</article-title><source>BMC Pharmacol. Toxicol.</source><year>2020</year><volume>21</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s40360-019-0380-0</pub-id><pub-id pub-id-type="pmid">31900219</pub-id><pub-id pub-id-type="pmcid">PMC6942351</pub-id></element-citation></ref><ref id="B49-ijms-27-00421"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ciftel</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ciftel</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Altuner</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Huseynova</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Yucel</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Mendil</surname><given-names>A.S.</given-names></name>
<name name-style="western"><surname>Sarigul</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Bulut</surname><given-names>S.</given-names></name>
</person-group><article-title>Effects of adenosine triphosphate, thiamine pyrophosphate, melatonin, and liv-52 on subacute pyrazinamide proliferation hepatotoxicity in rats</article-title><source>BMC Pharmacol. Toxicol.</source><year>2025</year><volume>26</volume><elocation-id>67</elocation-id><pub-id pub-id-type="doi">10.1186/s40360-025-00901-7</pub-id><pub-id pub-id-type="pmid">40128909</pub-id><pub-id pub-id-type="pmcid">PMC11931754</pub-id></element-citation></ref><ref id="B50-ijms-27-00421"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>European Parliament and Council</collab>
</person-group><article-title>Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes</article-title><source>Off. J. Eur. Union</source><year>2010</year><volume>L276</volume><fpage>33</fpage><lpage>79</lpage></element-citation></ref><ref id="B51-ijms-27-00421"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>du Sert</surname><given-names>N.P.</given-names></name>
<name name-style="western"><surname>Hurst</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Ahluwalia</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Alam</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Avey</surname><given-names>M.T.</given-names></name>
<name name-style="western"><surname>Baker</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Browne</surname><given-names>W.J.</given-names></name>
<name name-style="western"><surname>Clark</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Cuthill</surname><given-names>I.C.</given-names></name>
<name name-style="western"><surname>Dirnagl</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research</article-title><source>PLoS Biol.</source><year>2020</year><volume>18</volume><elocation-id>e3000410</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000410</pub-id><pub-id pub-id-type="pmid">32663219</pub-id><pub-id pub-id-type="pmcid">PMC7360023</pub-id></element-citation></ref><ref id="B52-ijms-27-00421"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kiani</surname><given-names>A.K.</given-names></name>
<name name-style="western"><surname>Pheby</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Henehan</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Sieving</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sykora</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Marks</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Falsini</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Capodicasa</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Miertus</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Ethical considerations regarding animal experimentation</article-title><source>J. Prev. Med. Hyg.</source><year>2022</year><volume>63</volume><fpage>E255</fpage><lpage>E266</lpage><pub-id pub-id-type="doi">10.15167/2421-4248/jpmh2022.63.2s3.2768</pub-id><pub-id pub-id-type="pmid">36479489</pub-id><pub-id pub-id-type="pmcid">PMC9710398</pub-id></element-citation></ref><ref id="B53-ijms-27-00421"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Erhan</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Altuner</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Demir</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Gulaboglu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Suleyman</surname><given-names>H.</given-names></name>
</person-group><article-title>Protective Effect of Adenosine Triphosphate Against Hydroxychloroquine Ototoxicity in Rats</article-title><source>Sci. Rep.</source><year>2025</year><volume>15</volume><fpage>38873</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-22644-5</pub-id><pub-id pub-id-type="pmid">41198710</pub-id><pub-id pub-id-type="pmcid">PMC12592334</pub-id></element-citation></ref><ref id="B54-ijms-27-00421"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Góth</surname><given-names>L.</given-names></name>
</person-group><article-title>A simple method for determination of serum catalase activity and revision of reference range</article-title><source>Clin. Chim. Acta</source><year>1991</year><volume>196</volume><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/0009-8981(91)90067-M</pub-id><pub-id pub-id-type="pmid">2029780</pub-id></element-citation></ref><ref id="B55-ijms-27-00421"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Bradford</surname><given-names>M.M.</given-names></name>
</person-group><article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title><source>Anal. Biochem.</source><year>1976</year><volume>72</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(76)90527-3</pub-id><pub-id pub-id-type="pmid">942051</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-27-00421-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(<bold>A</bold>,<bold>B</bold>) Effects of HCQ, ATP, and Liv-52 on oxidative stress parameters (MDA and tGSH) in rat liver tissue. Values are expressed as mean ± SD (n = 6). Statistical analyses were performed using one-way ANOVA followed by Tukey’s HSD post hoc test. *** <italic toggle="yes">p</italic> &lt; 0.001 vs. H group. Abbreviations: ATP: adenosine triphosphate; C: healthy group; H: hydroxychloroquine alone group; AH: ATP + hydroxychloroquine group; LH: Liv-52 + hydroxychloroquine group; ALH: ATP + Liv-52 + hydroxychloroquine group; MDA: malondialdehyde; tGSH: total glutathione.</p></caption><graphic orientation="portrait" position="float" xlink:href="ijms-27-00421-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="ijms-27-00421-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>(<bold>A</bold>,<bold>B</bold>) Effects of HCQ, ATP, and Liv-52 on oxidative stress parameters (SOD, CAT) in rat liver tissue. Values are expressed as mean ± SD (n = 6). Statistical analyses were performed using one-way ANOVA followed by Tukey’s HSD post hoc test. *** <italic toggle="yes">p</italic> &lt; 0.001 vs. H group. Abbreviations: ATP: adenosine triphosphate; C: healthy group; H: hydroxychloroquine alone group; AH: ATP + hydroxychloroquine group; LH: Liv-52 + hydroxychloroquine group; ALH: ATP + Liv-52 + hydroxychloroquine group; SOD: superoxide dismutase; CAT: catalase.</p></caption><graphic orientation="portrait" position="float" xlink:href="ijms-27-00421-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="ijms-27-00421-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>(<bold>A</bold>,<bold>B</bold>) Effects of HCQ, ATP, and Liv-52 on liver enzyme activities (ALT and AST) in rat liver tissue. Values are expressed as mean ± SD (n = 6). Statistical analyses were performed using Welch ANOVA followed by the Games–Howell post hoc test. *** <italic toggle="yes">p</italic> &lt; 0.001 vs. H group. Abbreviations: ATP: adenosine triphosphate; C: healthy group; H: hydroxychloroquine alone group; AH: ATP + hydroxychloroquine group; LH: Liv-52 + hydroxychloroquine group; ALH: ATP + Liv-52 + hydroxychloroquine group; ALT: alanine transaminase; AST: aspartate transaminase.</p></caption><graphic orientation="portrait" position="float" xlink:href="ijms-27-00421-g003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="ijms-27-00421-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Histopathological evaluation of liver tissue in experimental groups (H&amp;E staining). Representative photomicrographs from each group (n = 6). (<bold>A</bold>) Healthy group (C): normal hepatic parenchyma and portal area (×200). (<bold>B</bold>) HCQ-alone group (H): severe hepatic injury characterized by parenchymal destruction (double-headed arrow), hemorrhage (single-headed arrow), and edema (double arrow) (×400). (<bold>C</bold>) HCQ-only group (H): markedly dilated and congested blood vessel (×400). (<bold>D</bold>) ATP + HCQ group (AH): moderate hepatic damage with dilated congested blood vessel (single arrow), hemorrhage (double-headed arrow), and parenchymal lymphocyte infiltration (double arrow) (×200). (<bold>E</bold>) Liv-52 + HCQ group (LH): moderate hepatic damage characterized by dilated congested blood vessel (single arrow), hemorrhage (double-headed arrow), and parenchymal lymphocyte infiltration (double arrow) (×200). (<bold>F</bold>) ATP + Liv-52 + HCQ combination group (ALH): near-normal liver tissue morphology with only mild vascular congestion (red arrow) (×200).</p></caption><graphic orientation="portrait" position="float" xlink:href="ijms-27-00421-g004.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><table-wrap id="ijms-27-00421-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-27-00421-t001_Table 1</object-id><label>Table 1</label><caption><p>Quantitative assessment of histopathological changes in rat liver tissue.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Groups</th><th align="center" colspan="4" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Histopathological Grading Data</th></tr><tr><th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Parenchymal Destruction</th><th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hemorrhage</th><th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Edema</th><th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Vascular Dilatation/Congestion</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="1" valign="middle">C</td><td align="center" colspan="1" rowspan="1" valign="middle">0.00 (0.00–0.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.00 (0.00–0.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.00 (0.00–0.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">0.00 (0.00–0.00)</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">H</td><td align="center" colspan="1" rowspan="1" valign="middle">3.00 *** (2.00–3.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.00 *** (2.00–3.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.00 *** (3.00–3.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">3.00 *** (2.00–3.00)</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">AH</td><td align="center" colspan="1" rowspan="1" valign="middle">2.00 * (1.00–2.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.00 * (1.00–3.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.50 * (1.00–2.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.00 * (1.00–2.00)</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">LH</td><td align="center" colspan="1" rowspan="1" valign="middle">1.50 * (1.00–2.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">2.00 ** (2.00–3.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.50 * (1.00–2.00)</td><td align="center" colspan="1" rowspan="1" valign="middle">1.50 * (1.00–2.00)</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ALH</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.00 +++ (0.00–1.00)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.00 +++ (0.00–2.00)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.00 +++ (0.00–1.00)</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.00 +++ (0.00–2.00)</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Group comparisons</td><td align="center" colspan="4" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold><italic toggle="yes">p</italic>-values</bold>
</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">C vs. H</td><td align="center" colspan="1" rowspan="1" valign="middle">&lt;0.001</td><td align="center" colspan="1" rowspan="1" valign="middle">&lt;0.001</td><td align="center" colspan="1" rowspan="1" valign="middle">&lt;0.001</td><td align="center" colspan="1" rowspan="1" valign="middle">&lt;0.001</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">C vs. AH</td><td align="center" colspan="1" rowspan="1" valign="middle">0.030</td><td align="center" colspan="1" rowspan="1" valign="middle">0.037</td><td align="center" colspan="1" rowspan="1" valign="middle">0.067</td><td align="center" colspan="1" rowspan="1" valign="middle">0.058</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">C vs. LH</td><td align="center" colspan="1" rowspan="1" valign="middle">0.079</td><td align="center" colspan="1" rowspan="1" valign="middle">0.015</td><td align="center" colspan="1" rowspan="1" valign="middle">0.067</td><td align="center" colspan="1" rowspan="1" valign="middle">0.142</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">C vs. ALH</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">0.588</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">H vs. AH</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">0.358</td><td align="center" colspan="1" rowspan="1" valign="middle">0.588</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">H vs. LH</td><td align="center" colspan="1" rowspan="1" valign="middle">0.709</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">0.358</td><td align="center" colspan="1" rowspan="1" valign="middle">0.281</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">H vs. ALH</td><td align="center" colspan="1" rowspan="1" valign="middle">0.009</td><td align="center" colspan="1" rowspan="1" valign="middle">0.019</td><td align="center" colspan="1" rowspan="1" valign="middle">0.011</td><td align="center" colspan="1" rowspan="1" valign="middle">0.058</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">AH vs. LH</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">AH vs. ALH</td><td align="center" colspan="1" rowspan="1" valign="middle">0.709</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" valign="middle">1.000</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LH vs. ALH</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.603</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.000</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.000</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">K-W</td><td align="center" colspan="1" rowspan="1" valign="middle">23.673</td><td align="center" colspan="1" rowspan="1" valign="middle">23.692</td><td align="center" colspan="1" rowspan="1" valign="middle">25.026</td><td align="center" colspan="1" rowspan="1" valign="middle">22.376</td></tr><tr><td align="center" colspan="1" rowspan="1" valign="middle">df</td><td align="center" colspan="1" rowspan="1" valign="middle">4</td><td align="center" colspan="1" rowspan="1" valign="middle">4</td><td align="center" colspan="1" rowspan="1" valign="middle">4</td><td align="center" colspan="1" rowspan="1" valign="middle">4</td></tr><tr><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Asymptotic Sig.</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&lt;0.001</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&lt;0.001</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&lt;0.001</td><td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as median (min–max). * <italic toggle="yes">p</italic> &lt; 0.05 vs. C, ** <italic toggle="yes">p</italic> &lt; 0.01 vs. C, *** <italic toggle="yes">p</italic> &lt; 0.001 vs. C. +++ <italic toggle="yes">p</italic> &lt; 0.001 vs. H. n = 6 for all groups. Statistical analysis: Kruskal–Wallis test followed by Dunn’s post hoc test. Abbreviations: ATP: adenosine triphosphate; HCQ: hydroxychloroquine; C: healthy group; H: hydroxychloroquine alone group; AH: ATP + HCQ group; LH: Liv-52 + HCQ group; ALH: ATP + Liv-52 + HCQ group; df: degree of freedom.</p></fn></table-wrap-foot></table-wrap></floats-group></article>